The MOG antibody non-P42 epitope is predictive of a relapsing course in MOG antibody-associated disease.

ABSTRACT:

Background

Myelin oligodendrocyte glycoprotein (MOG) IgG seropositivity is a prerequisite for MOG antibody-associated disease (MOGAD) diagnosis. While a significant proportion of patients experience a relapsing disease, there is currently no biomarker predictive of disease course. We aim to determine whether MOG-IgG epitopes can predict a relapsing course in MOGAD patients.

Methods

MOG-IgG-seropositive confirmed adult MOGAD patients were included (n=202). Serum MOG-IgG and epitope binding were determined by validated flow cytometry live cell-based assays. Associations between epitopes, disease course, clinical phenotype, Expanded Disability Status Scale and Visual Functional System Score at onset and last review were evaluated.

Results

Of 202 MOGAD patients, 150 (74%)

SUBMITTER: Liyanage G 

PROVIDER: S-EPMC11103329 | biostudies-literature | 2024 May

REPOSITORIES: biostudies-literature